Rosuvastatin Explained

Verifiedfields:changed
Watchedfields:changed
Verifiedrevid:464383832
Width:275
Usan:Rosuvastatin calcium
Tradename:Crestor, others
Dailymedid:Rosuvastatin
Pregnancy Au:D
Pregnancy Au Comment:[1]
Routes Of Administration:Oral (by mouth)
Atc Prefix:C10
Atc Suffix:AA07
Atc Supplemental:
Legal Au:S4
Legal Ca:Rx-only
Legal Ca Comment:[2]
Legal Uk:POM
Legal Uk Comment:[3]
Legal Us:Rx-only
Legal Status:Rx-only
Bioavailability:20%[4]
Protein Bound:88%
Metabolism:Liver

CYP2C9 (major) and CYP2C19-mediated; ~10% metabolized

Metabolites:N-desmethyl rosuvastatin (major; 1/6–1/9 of rosuvastatin activity)
Elimination Half-Life:19 hours
Excretion:Feces (90%)
Index2 Label:calcium salt
Cas Number:287714-41-4
Cas Number2:147098-20-2
Unii:413KH5ZJ73
Unii2:83MVU38M7Q
Pubchem:446157
Pubchem2:5282455
Iuphar Ligand:2954
Drugbank:DB01098
Drugbank2:DBSALT000154
Chemspiderid:393589
Chemspiderid2:4445607
Kegg:D08492
Kegg2:D01915
Chebi:38545
Chebi2:77249
Chembl:1496
Chembl2:1744447
Pdb Ligand:FBI
Iupac Name:(3R,5S,6E)-7-[4-(4-Fluorophenyl)-2-(''N''-methylmethanesulfonamido)-6-(propan-2-yl)pyrimidin-5-yl]-3,5-dihydroxyhept-6-enoic acid
C:22
H:28
F:1
N:3
O:6
S:1
Smiles:OC(=O)C[C@H](O)C[C@H](O)\C=C\c1c(C(C)C)nc(N(C)S(=O)(=O)C)nc1c2ccc(F)cc2
Stdinchi:1S/C22H28FN3O6S/c1-13(2)20-18(10-9-16(27)11-17(28)12-19(29)30)21(14-5-7-15(23)8-6-14)25-22(24-20)26(3)33(4,31)32/h5-10,13,16-17,27-28H,11-12H2,1-4H3,(H,29,30)/b10-9+/t16-,17-/m1/s1
Stdinchikey:BPRHUIZQVSMCRT-VEUZHWNKSA-N

Rosuvastatin, sold under the brand name Crestor among others, is a statin medication, used to prevent cardiovascular disease in those at high risk and treat abnormal lipids. It is recommended to be used together with dietary changes, exercise, and weight loss. It is taken orally (by mouth).[5]

Common side effects include abdominal pain, nausea, headaches, and muscle pains.[5] Serious side effects may include rhabdomyolysis, liver problems, and diabetes.[5] Use during pregnancy may harm the baby.[5] Like all statins, rosuvastatin works by inhibiting HMG-CoA reductase, an enzyme found in the liver that plays a role in producing cholesterol.[5]

Rosuvastatin was patented in 1991, and approved for medical use in the United States in 2003.[5] [6] It is available as a generic medication.[5] In 2021, it was the thirteenth most commonly prescribed medication in the United States, with more than 32million prescriptions.[7] [8]

Medical uses

The primary use of rosuvastatin is for prevention of cardiovascular disease in those at high risk and the treatment of abnormal lipids.[5]

Effects on cholesterol levels

The effects of rosuvastatin on low-density lipoprotein (LDL) cholesterol are dose-related. Higher doses were more efficacious in improving the lipid profile of patients with hypercholesterolemia than milligram-equivalent doses of atorvastatin and milligram-equivalent or higher doses of simvastatin and pravastatin.[9]

Meta-analysis showed that rosuvastatin is able to modestly increase levels of high-density lipoprotein (HDL) cholesterol as well, as with other statins.[10] A 2014 Cochrane review determined there was good evidence for rosuvastatin lowering non-HDL levels linearly with dose.

Side effects and contraindications

Side effects are uncommon:[11]

The following rare side effects are more serious. Like all statins, rosuvastatin can possibly cause myopathy, rhabdomyolysis:[11]

Allergic reactions can develop:

Rosuvastatin has multiple contraindications, including hypersensitivity to rosuvastatin or any component of the formulation, active liver disease, elevation of serum transaminases, pregnancy, or breastfeeding.[12] Rosuvastatin is not prescribed nor used while pregnant, as it can cause serious harm to the fetus. In the case of breastfeeding, it is unknown whether rosuvastatin is passed through breastmilk.[13]

The risk of myopathy may be increased in Asian Americans: "Because Asians appear to process the drug differently, half the standard dose can have the same cholesterol-lowering benefit in those patients, though a full dose could increase the risk of side-effects, a study by the drug's manufacturer, AstraZeneca, indicated."[14] [15] [16] Therefore, the lowest dose is recommended in Asians.[17]

Myopathy

As with all statins, there is a concern of rhabdomyolysis, a severe undesired side effect. The U.S. Food and Drug Administration (FDA) has indicated that "it does not appear that the risk [of rhabdomyolysis] is greater with Crestor than with other marketed statins", but has mandated that a warning about this side-effect, as well as a kidney toxicity warning, be added to the product label.[18] [19]

Diabetes mellitus

Statins increase the risk of diabetes,[20] consistent with FDA's review, which reported a 27% increase in investigator-reported diabetes mellitus in rosuvastatin-treated people.[21]

Drug interactions

The following drugs can have negative interactions with rosuvastatin and should be discussed with the prescribing doctor:[11]

Grapefruit juice negatively interacts with several specific drugs in the statin class, but it has little or no effect on rosuvastatin.[23]

Structure

Rosuvastatin has structural similarities with most other statins, e.g., atorvastatin, cerivastatin and pitavastatin, but unlike other statins, rosuvastatin contains sulfur (in sulfonyl functional group).Crestor is a calcium salt of rosuvastatin, i.e. rosuvastatin calcium,[18] in which calcium replaces the hydrogen in the carboxylic acid group on the right of the skeletal formula at the top right of this page.

Mechanism of action

Rosuvastatin is a competitive inhibitor of the enzyme HMG-CoA reductase, having a mechanism of action similar to that of other statins.[24]

Putative beneficial effects of rosuvastatin therapy on chronic heart failure may be negated by increases in collagen turnover markers as well as a reduction in plasma coenzyme Q10 levels in patients with chronic heart failure.[25]

Pharmacodynamics

The dose-related magnitude of rosuvastatin on blood lipids was determined in a Cochrane systematic review in 2014. Over the dose range of 1 to 80 mg/day strong linear dose‐related effects were found; total cholesterol was reduced by 22.1% to 44.8%, LDL cholesterol by 31.2% to 61.2%, non-HDL cholesterol by 28.9% to 56.7% and triglycerides by 14.4% to 26.6%.[26]

Pharmacokinetics

Absolute bioavailability of rosuvastatin is about 20% and Cmax is reached in 3 to 5 hours; administration with food did not affect the AUC according to the original sponsor submitted clinical study and as per product label. However, a subsequent clinical study has shown a marked reduction in rosuvastatin exposure when administered with food.[27] It is 88% protein bound, mainly to albumin.[5] Fraction absorbed of rosuvastatin is frequently misquoted in the literature as approximately 0.5 (50%)[28] due to a miscalculated hepatic extraction ratio in the original submission package subsequently corrected by the FDA reviewer.[29]

Rosuvastatin is metabolized mainly by CYP2C9 and not extensively metabolized; approximately 10% is recovered as metabolite N-desmethyl rosuvastatin. It is excreted in feces (90%) primarily and the elimination half-life is approximately 19 hours.[5]

Both AUC and Cmax are approximately 2-fold higher in Asian patients compared to Caucasian patients given the same dose of rosuvastatin.

Society and culture

Rosuvastatin is the international nonproprietary name (INN).[30]

Economics

Because low- to moderate dose statins are strongly recommended by the United States Preventive Services Task Force (USPSTF) for primary prevention of cardiovascular disease in adults aged 40–75 years who are at risk,[31] the Patient Protection and Affordable Care Act (PPACA) in the United States requires most health insurance plans to cover the costs of these drugs without charging the insured patient a copayment or coinsurance, even if he or she has not yet reached his or her annual deductible.[32] [33] [34] Rosuvastatin 5 mg and 10 mg are examples of regimens meeting the USPTFS guideline;[31] however, insurers have discretion as to which low- and moderate-dose statin regimens to cover under this requirement,[35] and some only cover other statins.[36]

The drug was billed as a "super-statin" during its clinical development; the claim was that it offers high potency and improved cholesterol reduction compared to rivals in the class. The main competitors to rosuvastatin are atorvastatin and simvastatin. However, people can also combine ezetimibe with either simvastatin or atorvastatin and other agents on their own, for somewhat similar augmented response rates. some published information for comparing rosuvastatin, atorvastatin, and ezetimibe/simvastatin results is available, but many of the relevant studies are still in progress.[24]

First launched in 2003, sales of rosuvastatin were $129million and $908million in 2003, and 2004, respectively, with a total patient treatment population of over 4million by the end of 2004.Annual cost to the UK National Health Service (NHS) in 2018, for 5–40 mg rosuvastatin daily (of one person) was £24-40, compared to £10-20 for 20–80 mg simvastatin.[37]

In 2013, it was the fourth-highest selling drug in the United States, accounting for approximately $5.2billion in sales.[38] In 2021, it was the thirteenth most commonly prescribed medication in the United States, with more than 32million prescriptions.

Legal status

Rosuvastatin is approved in the United States for the treatment of high LDL cholesterol (dyslipidemia), total cholesterol (hypercholesterolemia), and/or triglycerides (hypertriglyceridemia).[39] In February 2010, rosuvastatin was approved by the FDA for the primary prevention of cardiovascular events.[40]

, rosuvastatin had been approved in 154 countries and launched in 56. Approval in the United States by the Food and Drug Administration (FDA) came on 13 August 2003.[41] [42]

Patent protection and generic versions

The main patent which protected rosuvastatin (RE37,314, which expired in 2016) was challenged as being an improper reissue of an earlier patent. This challenge was rejected in 2010, and thus patent protection did continue until 2016.[43] [44] [45] [46] [47]

In April 2016, the FDA approved the first generic version of rosuvastatin (from Watson Pharmaceuticals Inc).[48] In July 2016, Mylan gained approval for its generic rosuvastatin calcium.[49]

Debate and criticisms

In October 2003, several months after its introduction in Europe, Richard Horton, the editor of the medical journal The Lancet, criticized the way Crestor had been introduced. "AstraZeneca's tactics in marketing its cholesterol-lowering drug, rosuvastatin, raise disturbing questions about how drugs enter clinical practice and what measures exist to protect patients from inadequately investigated medicines," according to his editorial. The Lancet's editorial position is that the data for Crestor's superiority rely too much on extrapolation from the lipid profile data (surrogate end-points) and too little on hard clinical end-points, which are available for other statins that had been on the market longer. The manufacturer responded by stating that few drugs had been tested so successfully on so many patients. In correspondence published in The Lancet, AstraZeneca's CEO Tom McKillop called the editorial "flawed and incorrect" and slammed the journal for making "such an outrageous critique of a serious, well-studied medicine."[50]

In 2004, the consumer interest organization Public Citizen filed a Citizen's Petition with the FDA, asking that Crestor be withdrawn from the US market. On 11 March 2005, the FDA issued a letter to Sidney M. Wolfe of Public Citizen both denying the petition and providing an extensive detailed analysis of findings that demonstrated no basis for concerns about rosuvastatin compared with the other statins approved for marketing in the United States.[51] In 2015, Wolfe explained why he thought that "the drug should have been withdrawn and why it should not be used", due to the incidence of rhabdomyolysis, renal problems, and significant increase in glycated hemoglobin (HbA1C) and fasting insulin levels, and decreased insulin sensitivity in diabetic patients. Rosuvastatin indeed lowered cholesterol more than other statins, but Wolfe asked "what about actually improving health, preventing heart attacks and strokes?"[52]

Notes and References

  1. Web site: Rosuvastatin Use During Pregnancy . Drugs.com . 27 September 2019 . 14 March 2020 . 30 November 2020 . https://web.archive.org/web/20201130152103/https://www.drugs.com/pregnancy/rosuvastatin.html . live .
  2. Web site: Crestor Product information . Health Canada . 25 April 2012 . 9 July 2021 . 9 July 2021 . https://web.archive.org/web/20210709193244/https://health-products.canada.ca/dpd-bdpp/info.do?lang=en&code=71404 . live .
  3. Web site: Crestor 10mg film-coated tablets - Summary of Product Characteristics (SmPC) . (emc) . 29 September 2020 . 9 July 2021 . 9 July 2021 . https://web.archive.org/web/20210709193243/https://www.medicines.org.uk/emc/product/7559/smpc . live .
  4. Aggarwal RK, Showkathali R . Rosuvastatin calcium in acute coronary syndromes. Expert Opinion on Pharmacotherapy. June 2013. 14. 9. 1215–27. 10.1517/14656566.2013.789860. 23574635. 20221457 .
  5. Web site: Rosuvastatin Calcium Monograph for Professionals . Drugs.com . American Society of Health-System Pharmacists (AHFS) . 24 December 2018 . 24 December 2018 . https://web.archive.org/web/20181224170456/https://www.drugs.com/monograph/rosuvastatin-calcium.html . live .
  6. Book: Fischer J, Ganellin CR . Analogue-based Drug Discovery. 2006. John Wiley & Sons. 9783527607495. 473. 27 August 2020. 12 January 2023. https://web.archive.org/web/20230112030119/https://books.google.com/books?id=FjKfqkaKkAAC&pg=PA473. live.
  7. Web site: The Top 300 of 2021 . ClinCalc . 14 January 2024 . 15 January 2024 . https://web.archive.org/web/20240115223848/https://clincalc.com/DrugStats/Top300Drugs.aspx . live .
  8. Web site: Rosuvastatin - Drug Usage Statistics . ClinCalc . 14 January 2024.
  9. Jones PH, Davidson MH, Stein EA, Bays HE, McKenney JM, Miller E, Cain VA, Blasetto JW . Comparison of the efficacy and safety of rosuvastatin versus atorvastatin, simvastatin, and pravastatin across doses (STELLAR Trial) . Am J Cardiol . 2003 . 92 . 2 . 152–60 . 12860216 . 10.1016/S0002-9149(03)00530-7.
  10. McTaggart F . Effects of statins on high-density lipoproteins: a potential contribution to cardiovascular benefit. . Cardiovasc Drugs Ther. 22 . 4. August 2008 . 18553127 . 321–38 . 10.1007/s10557-008-6113-z . 2493531.
  11. Web site: Rosuvastatin. MedlinePlus. U.S. National Library of Medicine. 1 December 2012. 15 June 2012. 6 November 2012. https://web.archive.org/web/20121106160905/http://www.nlm.nih.gov/medlineplus/druginfo/meds/a603033.html. live.
  12. Web site: Crestor- rosuvastatin calcium tablet, film coated . DailyMed . 9 November 2018 . 14 March 2020 . 25 September 2020 . https://web.archive.org/web/20200925143007/https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=bb0f3b5e-4bc6-41c9-66b9-6257e2513512 . live .
  13. Web site: Rosuvastatin. LactMed. U.S. National Library of Medicine. 1 December 2012. https://web.archive.org/web/20160107115521/http://toxnet.nlm.nih.gov/cgi-bin/sis/search/f?.%2Ftemp%2F~jLYVIr%3A1. 7 January 2016. dead.
  14. News: FDA Advisory Targets Asian Patients . . 3 March 2005 . Alonso-Zaldivar R . 15 March 2020 . 5 March 2016 . https://web.archive.org/web/20160305071949/http://articles.latimes.com/2005/mar/03/nation/na-crestor3 . live .
  15. Wu HF, Hristeva N, Chang J, Liang X, Li R, Frassetto L, Benet LZ . Rosuvastatin Pharmacokinetics in Asian and White Subjects Wild Type for Both OATP1B1 and BCRP Under Control and Inhibited Conditions . J Pharm Sci . 106 . 9 . 2751–2757 . September 2017 . 28385543 . 5675025 . 10.1016/j.xphs.2017.03.027 .
  16. Lee VW, Chau TS, Leung VP, Lee KK, Tomlinson B . Clinical efficacy of rosuvastatin in lipid management in Chinese patients in Hong Kong . Chin. Med. J. . 122 . 23 . 2814–9 . December 2009 . 20092783 . 30 October 2019 . 30 October 2019 . https://web.archive.org/web/20191030192433/https://journals.lww.com/cmj/FullText/2009/12010/Clinical_efficacy_of_rosuvastatin_in_lipid.3.aspx . live .
  17. Web site: FDA Updates Crestor Warning Information . WebMD . 3 March 2005 . 14 March 2020 . 20 September 2020 . https://web.archive.org/web/20200920092759/https://www.webmd.com/cholesterol-management/news/20050303/fda-updates-crestor-warning-information . live .
  18. Web site: FDA Alert (03/2005) - Rosuvastatin Calcium (marketed as Crestor) Information . 14 March 2005 . U.S. Food and Drug Administration (FDA) . 20 March 2005 . https://web.archive.org/web/20050305033448/https://www.fda.gov/cder/drug/infopage/rosuvastatin/default.htm . 5 March 2005 . dead . - This page is subject to change; the date reflects the last revision date.
  19. Web site: Rosuvastatin Calcium (marketed as Crestor) Information . U.S. Food and Drug Administration (FDA) . 10 July 2015 . 14 March 2020 . 15 December 2019 . https://web.archive.org/web/20191215235005/https://www.fda.gov/drugs/postmarket-drug-safety-information-patients-and-providers/rosuvastatin-calcium-marketed-crestor-information . live .
  20. Sattar N, Preiss D, Murray HM, Welsh P, Buckley BM, de Craen AJ, Seshasai SR, McMurray JJ, Freeman DJ, Jukema JW, Macfarlane PW, Packard CJ, Stott DJ, Westendorp RG, Shepherd J, Davis BR, Pressel SL, Marchioli R, Marfisi RM, Maggioni AP, Tavazzi L, Tognoni G, Kjekshus J, Pedersen TR, Cook TJ, Gotto AM, Clearfield MB, Downs JR, Nakamura H, Ohashi Y, Mizuno K, Ray KK, Ford I . Statins and risk of incident diabetes: a collaborative meta-analysis of randomised statin trials.. Lancet. February 2010. 375. 9716. 735–42. 20167359. 10.1016/S0140-6736(09)61965-6. 11544414 .
  21. Web site: FDA Drug Safety Communication: Important safety label changes to cholesterol-lowering statin drugs . U.S. Food and Drug Administration (FDA) . 9 February 2019 . 15 March 2020 . 15 March 2020 . https://web.archive.org/web/20200315023515/https://www.fda.gov/drugs/drug-safety-and-availability/fda-drug-safety-communication-important-safety-label-changes-cholesterol-lowering-statin-drugs . live .
  22. Web site: Viberzi- eluxadoline tablet, film coated . DailyMed . 19 June 2018 . 14 March 2020 . 28 September 2020 . https://web.archive.org/web/20200928020742/https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=7821bd40-4c84-4984-951b-6436ae20421a . live .
  23. Bailey DG, Dresser G, Arnold JM . Grapefruit-medication interactions: forbidden fruit or avoidable consequences? . CMAJ . 185 . 4 . 309–316 . March 2013 . 23184849 . 3589309 . 10.1503/cmaj.120951 . free .
  24. Nissen SE, Nicholls SJ, Sipahi I, Libby P, Raichlen JS, Ballantyne CM, Davignon J, Erbel R, Fruchart JC, Tardif JC, Schoenhagen P, Crowe T, Cain V, Wolski K, Goormastic M, Tuzcu EM . Effect of very high-intensity statin therapy on regression of coronary atherosclerosis: the ASTEROID trial . JAMA . 295 . 13 . 1556–65 . April 2006 . 16533939 . 10.1001/jama.295.13.jpc60002 . doi .
  25. Ashton E, Windebank E, Skiba M, Reid C, Schneider H, Rosenfeldt F, Tonkin A, Krum H . Why did high-dose rosuvastatin not improve cardiac remodeling in chronic heart failure? Mechanistic insights from the UNIVERSE study . Int J Cardiol . 146. 3. 404–7. February 2011 . 20085851 . 10.1016/j.ijcard.2009.12.028 .
  26. Rosuvastatin for lowering lipids . The Cochrane Database of Systematic Reviews. 11 . Adams SP, Sekhon SS, Wright JM . November 2014 . 2014 . CD010254. 10.1002/14651858.cd010254.pub2. 25415541. 6463960 . free . doi .
  27. Li Y, Jiang X, Lan K, Zhang R, Li X, Jiang Q . October 2007. Pharmacokinetic properties of rosuvastatin after single-dose, oral administration in Chinese volunteers: a randomized, open-label, three-way crossover study. Clinical Therapeutics. 29. 10. 2194–203. 10.1016/j.clinthera.2007.10.005. 18042475 .
  28. Bergman E, Lundahl A, Fridblom P, Hedeland M, Bondesson U, Knutson L, Lennernäs H . December 2009. Enterohepatic disposition of rosuvastatin in pigs and the impact of concomitant dosing with cyclosporine and gemfibrozil . Drug Metabolism and Disposition. 37. 12. 2349–58. 10.1124/dmd.109.029363. 19773540. 24783238 .
  29. Web site: Page 45 of FDA Drug Approval Package, Clinical Pharmacology Biopharmaceutics Review(s) (PDF). 29 January 2004. U.S. Food and Drug Administration (FDA). 22 June 2016. 28 August 2016. https://web.archive.org/web/20160828094451/http://www.accessdata.fda.gov/drugsatfda_docs/nda/2003/21-366_Crestor.cfm. live.
  30. Web site: International Nonproprietary Names for Pharmaceutical Substances (INN). Recommended International Nonproprietary Names (Rec. INN): List 45 . World Health Organization . 29 November 2016 . 50 . 2001 . 18 May 2016 . https://web.archive.org/web/20160518192927/http://www.who.int/medicines/publications/druginformation/innlists/RL45.pdf . live .
  31. Statin Use for the Primary Prevention of Cardiovascular Disease in Adults: Recommendation Statement . American Family Physician . 95 . 2 . January 2017 . 9 May 2022 . 3 August 2020 . https://web.archive.org/web/20200803014843/https://www.aafp.org/afp/2017/0115/od1.html . live .
  32. Web site: Affordable Care Act (ACA)-Essential Health Benefit (EHB) Zero Dollar Copay Preventive Medication List White Paper . Arizona Department of Administration Human Resources . State of Arizona . 8 May 2022 . 3 March 2022 . https://web.archive.org/web/20220303022220/https://benefitoptions.az.gov/sites/default/files/PHARM_F_Essential_Health_Benefit_List.pdf . live .
  33. Web site: Preventive care benefits for adults . . . 7 May 2022 . 7 May 2022 . https://web.archive.org/web/20220507192559/https://www.healthcare.gov/preventive-care-adults/ . live .
  34. Web site: Preventive Services Covered by Private Health Plans under the Affordable Care Act . 4 August 2015 . . 7 May 2022 . 2 May 2022 . https://web.archive.org/web/20220502082404/https://www.kff.org/health-reform/fact-sheet/preventive-services-covered-by-private-health-plans/ . live .
  35. Web site: Affordable Care Act Implementation FAQs - Set 12 . CMS . 22 April 2013 . 7 May 2022 . 5 May 2022 . https://web.archive.org/web/20220505071209/https://www.cms.gov/CCIIO/Resources/Fact-Sheets-and-FAQs/aca_implementation_faqs12 . live .
  36. Web site: SignatureValue Zero Cost Share Preventive Medications PDL. September 2021. Uhc.com. 26 May 2022. 5 February 2022. https://web.archive.org/web/20220205144210/https://www.uhc.com/content/dam/uhcdotcom/en/Pharmacy/PDFs/UHC-SignatureValue-Formulary-PPACA-ZeroCost-Preventive-Meds-Eff-Sept-2021.pdf. live.
  37. Web site: COST COMPARISON CHARTS. REGIONAL DRUG AND THERAPEUTICS CENTRE (NEWCASTLE). August 2018. 4 December 2018. 20 October 2018. https://web.archive.org/web/20181020032741/http://gmmmg.nhs.uk/docs/cost_comparison_charts.pdf. dead.
  38. Web site: Top 100 Drugs for Q2 2013 by Sales. 24 August 2013. 23 June 2018. https://web.archive.org/web/20180623222024/https://www.drugs.com/stats/top100/sales. live.
  39. Web site: Core Data Sheet, Crestor Tablets . 17 June 2003 . . 20 March 2005 . https://web.archive.org/web/20050508053622/http://www.crestor.info/gUserFiles/CRESTOR_CDS_10_40_mg_FINAL_170603.pdf . 8 May 2005 . dead . mdy-all . - NOTE: this is provider-oriented information and should not be used without the supervision of a physician.
  40. Supplement approval - CRESTOR (rosuvastatin calcium) Tablets . U.S. Food and Drug Administration (FDA). NDA 21366/S-016. Colman EC . 8 February 2010. 31 October 2010. 17 October 2012. https://web.archive.org/web/20121017170917/http://www.accessdata.fda.gov/drugsatfda_docs/appletter/2010/021366s016ltr.pdf. live.
  41. Web site: Drug Approval Package: Crestor (Rosuvastatin Calcium) NDA #021366 . U.S. Food and Drug Administration (FDA) . 29 January 2004 . 15 March 2020 . 6 August 2020 . https://web.archive.org/web/20200806005318/https://www.accessdata.fda.gov/drugsatfda_docs/nda/2003/21-366_Crestor.cfm . live .
  42. News: FDA Approves New Drug for Lowering Cholesterol . 12 August 2003 . U.S. Food and Drug Administration (FDA) . 20 March 2005 . https://web.archive.org/web/20050207153150/https://www.fda.gov/bbs/topics/ANSWERS/2003/ANS01247.html . 7 February 2005 . dead .
  43. Web site: AstraZeneca's Crestor patent upheld;No generic competition until 2016. Delawareonline.com. 26 May 2022.
  44. Crestor Patent Upheld By US Court. 25 April 2012. AstraZeneca. 29 June 2010. PR Newswire. 27 November 2020. https://web.archive.org/web/20201127003059/https://www.prnewswire.com/news-releases/crestor-patent-upheld-by-us-court-97435724.html. live.
  45. News: U.S. judge rules AstraZeneca Crestor patent valid. 25 April 2012. 29 June 2010. Reuters. Berkrot B, Hals T . 12 March 2016. https://web.archive.org/web/20160312124530/http://www.reuters.com/article/astrazeneca-crestor-idUSN2917115320100629. live.
  46. News: AstraZeneca patent upheld. https://archive.today/20130131145710/http://pqasb.pqarchiver.com/delawareonline/access/2074695931.html?FMT=ABS&date=Jul+01,+2010. dead. 31 January 2013. 25 April 2012. 1 July 2010. The News Journal. Wilmington, Delaware. Starkey J . subscription .
  47. Crestor US patent upheld by Court of Appeals for the Federal Circuit . AstraZeneca . 14 December 2012 . 9 July 2021 . 9 July 2021 . https://web.archive.org/web/20210709193242/https://www.astrazeneca.com/media-centre/press-releases/2012/CRESTOR-US-patent-upheld-by-Court-of-Appeals-for-the-Federal-Circuit-14122012.html . live .
  48. Web site: FDA approves first generic Crestor. U.S. Food and Drug Administration (FDA). 3 May 2016. 29 April 2016. 15 March 2020. https://web.archive.org/web/20200315024145/https://www.fda.gov/news-events/press-announcements/fda-approves-first-generic-crestor. live.
  49. Mylan Launches Generic Crestor Tablets . 20 July 2016 . . PR Newswire . 15 March 2020 . 9 March 2021 . https://web.archive.org/web/20210309012223/https://www.prnewswire.com/news-releases/mylan-launches-generic-crestor-tablets-300301446.html . live .
  50. Horton R . The statin wars: why AstraZeneca must retreat . Lancet . 362 . 9393 . 1341 . October 2003 . 14585629 . 10.1016/S0140-6736(03)14669-7 . 39528790 . doi . free .
    McKillop T . The statin wars . Lancet . 362 . 9394 . 1498 . November 2003 . 14602449 . 10.1016/S0140-6736(03)14698-3. 5300990 . free .
  51. Web site: U.S. Food and Drug Administration (FDA) . Docket No. 2004P-0113/CP1 . 2 July 2020 . 2 July 2020 . https://web.archive.org/web/20200702175551/https://www.regulations.gov/contentStreamer?documentId=FDA-2004-P-0009-0004&attachmentNumber=1&contentType=pdf . live .
  52. Wolfe S . Rosuvastatin: winner in the statin wars, patients' health notwithstanding . BMJ. 350 . March 2015 . 10.1136/bmj.h1388. free . h1388 . doi . 25787130 .

This article is licensed under the GNU Free Documentation License. It uses material from the Wikipedia article "Rosuvastatin".

Except where otherwise indicated, Everything.Explained.Today is © Copyright 2009-2024, A B Cryer, All Rights Reserved. Cookie policy.